NMRA-335140

Phase 3

50%

Phase 3

Development Phase

2

Upcoming Catalysts

0

Historical Events

0

Regulatory Approvals

Upcoming Catalysts

May 2026~

NMRA$307M⭐Phase 3

NMRA-335140 Phase 3 Results Expected

NMRA-335140 • Major Depressive Disorder

Feb 2026~

NMRA$307M⭐Phase 3

NMRA-335140 Phase 3 Results Expected

NMRA-335140 • Major Depressive Disorder

Drug Information

Target Indication

Major Depressive Disorder

Clinical Trial

Last updated: 12/4/2025

Developer

NMRA

Neumora Therapeutics, Inc.

Related Pipeline

Major Depressive Disorder

Major Depressive Episode Associated With Bipolar II Disorder